Investor Relations

Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area of oncology with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has promising product candidates in clinical and late preclinical development and has entered into strategic collaborations with leading global pharmaceutical companies.

Recent News > MORE
Date Title  
Monday, May 15, 2017 Five Prime Welcomes Garry Nicholson to Board of Directors
Thursday, May 4, 2017 Five Prime Announces First Quarter 2017 Results and Provides Business Update
Upcoming and Recent Events > MORE
Date Title  
Thursday, May 4, 2017
4:30 PM ET
Five Prime Therapeutics, Inc. 2017 Q1 Quarterly Earnings Call
Supporting Materials
PDF View Presentation 796.0 KB   Add to Briefcase
Thursday, February 23, 2017
4:30 PM ET
Five Prime Therapeutics, Inc. 2016 Q4 Quarterly Earnings Call
Supporting Materials
PDF View Presentation 696.1 KB   Add to Briefcase
Thursday, February 16, 2017
11:00 AM ET
LEERINK Partners 6th Annual Global Healthcare Conference
Supporting Materials
PDF View Presentation  3.1 MB   Add to Briefcase

FPRX (Common Stock)

Exchange
NASDAQ
Price
28.95
Change (%)
0.00
Volume
N/A

Data as of 4:00 PM ET on Friday, May 26, 2017
Minimum 20 minute delay
Refresh quote
Powered By eSignal, Inc.